Dyne Therapeutics Quote - DYN

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

14.79

Bid

13.35

Offer

14.96

Volume

0.00 Day's Range 0.00

13.235 52 Week Range 47.45

Market Cap

1.505B

Previous Close

14.79

Open

Last Trade

14.79

Last Trade Time

20:05:03

Financial Volume

VWAP

Average Volume (3m)

1,693,430

Shares Outstanding

101,765,958

Dividend Yield

PE Ratio

-6.38

Earnings Per Share (EPS)

-2.32

Revenue

Net Profit

-235.94M

Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy.

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.dyne-tx.com

Headquarters

Wilmington, Delaware, USA

Founded

Dyne Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker DYN. The last closing price for Dyne Therapeutics was US$14.79. Over the last year, Dyne Therapeutics shares have traded in a share price range of US$ 13.235 to US$ 47.45.

Dyne Therapeutics currently has 101,765,958 shares in issue. The market capitalisation of Dyne Therapeutics is US$1.51 billion. Dyne Therapeutics has a price to earnings ratio (PE ratio) of -6.38.

Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming...

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

- Company Anticipates Submitting for U.S. Accelerated Approval in H1 2026 - WALTHAM, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage...

Form 8-K - Current report

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101

- DYNE-101 in DM1: Dyne plans to initiate global Registrational Expansion Cohort of ACHIEVE trial with registrational dose of 6.8 mg/kg Q8W following study data showing splicing correction and...

Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming...

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET

WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	1.39	10.3731343284	13.4	14.955	13.33	1605274	14.1754399	CS
4	-8.94	-37.6738305942	23.73	23.73	13.235	3298630	14.68264387	CS
12	-14.33	-49.2101648352	29.12	35.68	13.235	1693430	19.82117483	CS
26	-21.5	-59.2449710664	36.29	47.45	13.235	1436155	27.326491	CS
52	-6.22	-29.6049500238	21.01	47.45	13.235	1329213	28.56882861	CS
156	8	117.820324006	6.79	47.45	4.3	782320	21.8209281	CS
260	-8.66	-36.9296375267	23.45	47.45	4.3	625382	21.20727718	CS

DYN - Frequently Asked Questions (FAQ)

What is the current Dyne Therapeutics share price?

The current share price of Dyne Therapeutics is US$ 14.79

How many Dyne Therapeutics shares are in issue?

Dyne Therapeutics has 101,765,958 shares in issue

What is the market cap of Dyne Therapeutics?

The market capitalisation of Dyne Therapeutics is USD 1.51B

What is the 1 year trading range for Dyne Therapeutics share price?

Dyne Therapeutics has traded in the range of US$ 13.235 to US$ 47.45 during the past year

What is the PE ratio of Dyne Therapeutics?

The price to earnings ratio of Dyne Therapeutics is -6.38

What is the reporting currency for Dyne Therapeutics?

Dyne Therapeutics reports financial results in USD

What is the latest annual profit for Dyne Therapeutics?

The latest annual profit of Dyne Therapeutics is USD -235.94M

What is the registered address of Dyne Therapeutics?

The registered address for Dyne Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the Dyne Therapeutics website address?

The website address for Dyne Therapeutics is www.dyne-tx.com

Which industry sector does Dyne Therapeutics operate in?

Dyne Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
OPOFOld Point Financial Corporation	US$ 39.51 (58.99%)	4
TWINTwin Disc Inc	US$ 17.88 (58.93%)	158
IBACIB Acquisition Corporation	US$ 16.24 (58.90%)	2
ADSEADD TEC Energy PLC	US$ 23.39 (56.66%)	12
AFRIForafric Global PLC	US$ 14.99 (56.15%)	19
SBFGSB Finanical Group Inc	US$ 12.22 (-46.85%)	10
THRYThryv Holdings Inc	US$ 10.01 (-46.01%)	4
IROQIF Bancorp Inc	US$ 15.00 (-38.17%)	201
AURAAura Biosciences Inc	US$ 5.01 (-37.38%)	1
WMPNWilliam Penn Bancorporation	US$ 8.00 (-35.22%)	201
SXTP60 Degrees Pharmaceuticals Inc	US$ 0.807 (35.18%)	15.68M
CYNCYNGN Inc	US$ 0.0783 (10.28%)	14.57M
UPCUniverse Pharmaceuticals Inc	US$ 0.31 (14.86%)	8.14M
SFHGSamfine Creation Holdings Group Ltd	US$ 1.535 (53.50%)	6M
RIMEAlgorhythm Holdings Inc	US$ 0.0251 (2.87%)	5.5M